The goal of the University of Iowa / Mayo Clinic Lymphoma SPORE (UI/MC SPORE) Developmental Research Program is to support innovative, scientifically sound projects that investigate a question pertaining to translational lymphoma research. This program was highly successful with past and current support over the past 4 years going to 20 different developmental research projects to date for 1-2 years each. Seven of these projects have received external, peer-reviewed NCI funding, including 3 R-01 grants. Most of the others are ongoing, or funding is being sought. In addition, all 4 of the full projects in this renewal application developed in part from contributions made by Developmental Research Projects. The Developmental Research Program will provide up to $50,000 for one year ($25,000 from SPORE funds and a matching $25,000 from institutional resources) to each of four projects each year with the possibility of a second year of support based on progress. It is anticipated that support of developmental research projects will continue to result in the generation of new hypotheses that will be tested in full UI/MC SPORE-sponsored projects or through peer reviewed external grant support. The long-term goal of the UI/MC SPORE program is to translate the findings generated by developmental projects into a reduction in the incidence and mortality rates of lymphoma. More specifically, the objectives of the Developmental Research Program are to: (1) encourage innovative translationally-relevant laboratory, population and clinical studies;(2) foster extensive collaboration between basic science, population science and clinical disciplines in translational research in lymphoma;and, (3) generate new hypotheses to be tested in large-scale research projects or clinical trials that may lead to significant reduction of lymphoma incidence and mortality. Brief outlines of four developmental research projects from investigators at the University of Iowa and the Mayo Clinic are included to demonstrate the depth and breath of ongoing research that can be applied to the translational lymphoma research at these institutions and could be eligible for UI/MC SPORE Developmental Program support.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Iowa
Iowa City
United States
Zip Code
Chapuy, Bjoern; Stewart, Chip; Dunford, Andrew J et al. (2018) Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24:679-690
Leal, Alexis D; Allmer, Cristine; Maurer, Matthew J et al. (2018) Variability of performance status assessment between patients with hematologic malignancies and their physicians. Leuk Lymphoma 59:695-701
Leelakanok, Nattawut; Geary, Sean M; Salem, Aliasger K (2018) Antitumor Efficacy and Toxicity of 5-Fluorouracil-Loaded Poly(Lactide Co-glycolide) Pellets. J Pharm Sci 107:690-697
Ghesquières, Hervé; Larrabee, Beth R; Casasnovas, Olivier et al. (2018) A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts. Br J Haematol 180:286-290
Sharma, Ayush; Oishi, Naoki; Boddicker, Rebecca L et al. (2018) Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. Blood 131:2262-2266
Fama, Angelo; Xiang, Jinhua; Link, Brian K et al. (2018) Human Pegivirus infection and lymphoma risk and prognosis: a North American study. Br J Haematol 182:644-653
Jalali, Shahrzad; Price-Troska, Tammy; Paludo, Jonas et al. (2018) Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. Blood Adv 2:1985-1997
Bachy, Emmanuel; Maurer, Matthew J; Habermann, Thomas M et al. (2018) A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. Blood 132:49-58
Franqui-Machin, Reinaldo; Hao, Mu; Bai, Hua et al. (2018) Destabilizing NEK2 overcomes resistance to proteasome inhibition in multiple myeloma. J Clin Invest 128:2877-2893
Ghahramani, Grant K; Goetz, Kirsten E; Liu, Vincent (2018) Dermoscopic characterization of cutaneous lymphomas: a pilot survey. Int J Dermatol 57:339-343

Showing the most recent 10 out of 387 publications